

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

GLAXOSMITHKLINE PLC
Form 6-K
April 25, 2008

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION
Washington D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934

For period ending April 25, 2008

GlaxoSmithKline plc
(Name of registrant)

980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address of principal executive offices)

Indicate by check mark whether the registrant files or
will file annual reports under cover Form 20-F
or Form 40-F

Form 20-F Form 40-F
--

Indicate by check mark whether the registrant by furnishing the
information contained in this Form is also thereby furnishing the
information to the Commission pursuant to Rule 12g3-2(b) under the
Securities Exchange Act of 1934.

Yes No
--

Notification of Transactions of Directors, Persons Discharging Managerial
Responsibility or Connected Persons

The Administrators of the GlaxoSmithKline Annual Investment Plan notified the Company and the under mentioned persons on 25 April 2008 of an increase in their interests in Ordinary shares at a price of GBP11.01 per share following the re-investment of the dividend paid to shareholders on 10 April 2008:-

Dr M M Slaoui	319
Mr M Dunoyer	154
Mr D Learmouth	27

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

Dr D Pulman
Mr A P Witty

235
143

This notification relates to transactions notified in accordance with Disclosure and Transparency Rule 3.1.4R(1) (a).

S M Bicknell
Company Secretary

25 April 2008

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GlaxoSmithKline plc
(Registrant)

Date: April 25, 2008

By: VICTORIA WHYTE

Victoria Whyte
Authorised Signatory for and on
behalf of GlaxoSmithKline plc